Secondary Logo

Journal Logo

Original Articles

Optimal waiting period for fresh embryo transfer after hysteroscopic adhesiolysis

a retrospective cohort study

Deng, Ke1,2; Song, Xiao-Hua1,2,3; Han, Xue-Mei4; Kong, Wei-Ya1,2; Liu, Wei1,2; Han, Ting2; Yan, Lei1,2

Editor(s): Wang, Ning-Ning

Author Information
doi: 10.1097/CM9.0000000000000456

Abstract

Introduction

Intra-uterine adhesions (IUAs; Asherman syndrome) are composed of fibrotic tissue, which may result in the adherence of opposing surfaces, producing dense or filmy adhesion bands that can lead to partial or complete closure of the uterine cavity. It is possible that after injury to the endometrium, fibrosis may follow with the potential of adhesion formation.[1–3] Clinical features of IUA include menstrual abnormalities (usually amenorrhea or hypomenorrhea), infertility, recurrent spontaneous abortion, and repeated failure of embryo implantation.[4,5]

Implantation remains the rate-limiting step for the success of in vitro fertilization (IVF) treatment, with approximately two thirds of implantation failures resulting from inadequate uterine receptivity.[6] In endometrial fibrosis, the lack of sufficient normal endometrial tissue to support implantation and defective vascularization of the residual endometrial tissue will reduce uterine receptivity.[1,7] Therefore, the treatment of IUA may significantly improve endometrial receptivity.

Hysteroscopic surgery is the primary treatment for IUA, but there is lack of an effective method to prevent the recurrence of IUA.[2,5,8–11] A previous study showed a variation in endometrial recovery time following different hysteroscopic surgeries, and that the wounds from adhesiolysis healed within 2 months.[12] Therefore, we believe that the recovery time after surgery is too long to result in recurrence of IUA, or the time is too short to affect the embryo transfer (ET).[12]

In 2016, the relationship between the time point for the start of fresh IVF-ET cycles after hysteroscopic polypectomy and the outcome of pregnancy was studied by Pereira et al.[13] Their study suggested that the elapsed timeframe between hysteroscopic polypectomy and the start of fresh IVF-ET cycles does not affect cycle outcomes.

Thus far, very few studies have been conducted regarding the optimal time interval between hysteroscopic adhesiolysis and ET. This time interval may be related to the severity and extent of IUA, and investigation of the effects of different time intervals may define more optimal conditions for assisted reproductive technology (ART). In this study, we investigated whether the interval between hysteroscopic adhesiolysis and ET affects IVF cycle outcomes.

Methods

Ethics approval

This retrospective cohort study was approved by the Institutional Review Board of the Reproductive Hospital Affiliated to Shandong University (No. 2018-29). All participants had given their informed consent.

Study design

The inclusion criteria were as follows: (1) women aged 26 to 44 years; (2) women diagnosed with IUAs by hysteroscopy undergoing hysteroscopic adhesiolysis before fresh IVF-ET or intra-cytoplasmic sperm injection (ICSI)-ET cycles; (3) had undergone the first fresh ET cycle after surgery; and (4) the surgery was performed between January 2014 and September 2017 in our hospital. The exclusion criteria were as follows: (1) patients with oocyte donor treatment cycles, (2) a history of hysteroscopic adhesiolysis before this surgery, and (3) presence of other comorbidities that prevented matching (eg, chromosomal abnormalities).

Diagnostic hysteroscopy and vaginal ultrasonography were performed routinely on all patients before surgery.[1,14] The surgery was performed by several experienced hysteroscopic surgeons. When needed, laparoscopy was also performed to inspect for tubal patency or pelvic inflammation. The severity and extent of IUA were scored according to classification systems of the American Fertility Society (AFS), the European Society for Gastrointestinal Endoscopy (ESGE), and the Chinese IUA scoring system.[15–17]

To prevent recurrence of IUAs, doctors often inserted an intra-uterine device (IUD) or Foley balloon into the uterine cavity, administered patients with estrogen supplementation to enhance endometrial proliferation, and performed second-look office hysteroscopy. All patients were monitored and managed according to the standard clinical protocol used by the hospital after hysteroscopic adhesiolysis.[18] No patients were lost for follow-up. All patients were classified into three groups according to the interval between the surgery and the fresh ET: Group 1 was less than 90 days; Group 2 was 90 to 180 days, and Group 3 was more than 180 days. Patients were further classified into several subgroups according to the AFS scores to identify the relationship between severity of IUA and subsequent pregnancy outcomes of fresh ET cycles.

Main outcomes of all the included patients

Recorded baseline characteristics included age, body mass index (BMI), hormone levels on days 1 to 3 of the menstrual period (basal follicle-stimulating hormone [FSH], luteinizing hormone [LH], progesterone [P], and estradiol [E2]). We also recorded pre-operative endometrial thickness, the indication for IVF (male factor, tubal factor, or other), and the type of infertility (primary or secondary). Recorded controlled ovarian stimulation (COS) characteristics were as follows: total dosage and startup dosage of gonadotropin (Gn), protocol type, total number of mature oocytes (>14 mm), peak endometrial thickness, number of embryos transferred, and days to ET. The primary outcome was live-birth rate, which was defined as delivery of any viable infant at 28 weeks or more of gestation during the first fresh ET.[19] Other outcomes included the rates of biochemical pregnancy, clinical pregnancy, and ongoing pregnancy, and also included clinical miscarriage (MR), stillbirth, and biochemical MR.[20] Other characteristics included the surgical procedure (hysteroscopic electrotomy or cold knife) and severity classification (by the AFS, ESGE, and Chinese IUA scoring systems).

Statistical analysis

SPSS 22.0 (IBM, Armonk, NY, USA) was used for data analysis. Quantitative data are expressed as mean ± standard deviation and percentage. Numerical data included age, BMI, basal E2, P, FSH, and LH, and pre-operative endometrial thickness, startup dosage of Gn, total dosage of Gn, total number of mature oocytes, and peak endometrial thickness. Categorical data included the indication for IVF, type of infertility, protocol type, number of embryos transferred, days to ET, surgical procedure, severity classification, and pregnancy outcomes. Analysis of variance or non-parametric tests were used to test numerical data. The Pearson's Chi-squared test was used to test categorical data. A P < 0.05 was considered statistically significant. Adjusted odds ratio (OR) and 95% confidence intervals (95% CI) were estimated using logistic regression. Inclusion of the data into the two-category models eliminated confounders when there were differences between the groups (P < 0.1) in baseline characteristics.

Results

During the study period, 1369 patients in our institution were diagnosed with IUA and underwent hysteroscopic adhesiolysis before fresh IVF-ET or ICSI cycles. Of these patients, 312 patients met the inclusion criteria and were grouped as follows: 112 (35.9%) in Group 1, 137 (43.9%) in Group 2, and 63 (20.2%) in Group 3 [Figure 1].

Figure 1
Figure 1:
Flowchart of this study on the optimal waiting period for fresh embryo transfer after hysteroscopic adhesiolysis.

Clinical characteristics of the 312 women are shown in Table 1. There were no significant differences among the three groups in terms of age: the mean age of Groups 1, 2, and 3 were 34.7 ± 5.0, 33.6 ± 5.4, and 33.4 ± 4.8 years, respectively. Recorded baseline characteristics of BMI, hormone levels on days 1 to 3 of the menstrual period (basal FSH, LH, P, and E2), pre-operative endometrial thickness, indication for IVF (male factor, tubal factor, or other), and type of infertility (primary or secondary) showed no significant differences among the groups.

Table 1
Table 1:
Baseline characteristics of patients who underwent hysteroscopic adhesiolysis.

The COS characteristics were compared among the three groups. No significant differences were observed for the peak endometrial thickness among the three groups. The peak endometrial thicknesses were 0.89 ± 0.22 mm, 0.89 ± 0.19 mm, and 0.90 ± 0.20 mm in Groups 1, 2, and 3, respectively. There were no statistical differences in mean age, total dosage and startup dosage of gonadotropin (Gn), protocol type, total number of mature oocytes (>14 mm), number of embryos transferred, and days of ET. The results are shown in Table 2.

Table 2
Table 2:
Controlled ovarian stimulation characteristics of patients who underwent hysteroscopic adhesiolysis.

We further compared the main outcomes of the IVF/ICSI treatment cycles undertaken by the three groups. After adjusting the “long protocol” of ovary stimulation and total dosage of Gn by logistic regression analysis, live-birth rate showed a significant change in three groups (OR = 0.676, 95% CI 0.477–0.960; P = 0.029), and the frequency of live births after fresh-ET in Group 2 (40.1%) was significantly higher than that in Group 1 (17.9%; χ2 = 14.545, P < 0.001). There were no significant between-group differences in the incidence of biochemical pregnancy, clinical, and ongoing pregnancy, clinical pregnancy abortion, biochemical pregnancy abortion, and stillbirth [Table 3].

Table 3
Table 3:
Pregnancy outcome of patients who underwent hysteroscopic adhesiolysis.

To analyze the effect of the severity of IUAs on the outcome, we compared the rate of severity classification among the three groups. We used three scoring methods to scale the severity, including AFS, ESGE, and the Chinese IUA scoring system. There were no significant differences found [Table 4]. Moreover, we analyzed the effect of different surgical procedures on the outcome, including hysteroscopic electrotomy and cold knife surgery. There were no significant differences among the three groups [Supplemental Table 1, http://links.lww.com/CM9/A97]. In addition, to provide more precise recommendations regarding ET to patients with different degrees of IUAs, patients were classified into three subgroups according to the AFS scores. We compared only mild and moderate patients because the number of severe patients was too small. In both the mild and moderate groups, significant differences for the live-birth rate at three different time intervals were observed [Tables 5 and 6]. In the mild groups, Group 2 (42.6%) had a higher frequency of live births than Group 1 (22.0%; χ2 = 8.413, P = 0.004). In the moderate groups, Group 2 (35.7%) had a higher frequency of live births than Group 1 (6.7%; χ2 = 8.187, P = 0.004).

Table 4
Table 4:
Severity classification of patients who underwent hysteroscopic adhesiolysis.
Table 5
Table 5:
Pregnancy outcomes of AFS-mild patients who underwent hysteroscopic adhesiolysis.
Table 6
Table 6:
Pregnancy outcomes of AFS-moderate subgroup patients who underwent hysteroscopic adhesiolysis.

To observe the pregnancy outcomes more intuitively, we prepared a curve of the relationship between the time window and pregnancy outcomes to reflect the change in pregnancy rates. This curve showed a trend toward higher clinical pregnancy and live-birth rates, and also a trend toward a lower miscarriage rate, for Group 2 compared with Groups 1 and 3. The results are shown in Supplementary Figure 1, http://links.lww.com/CM9/A97.

There were no significant between-group differences in age, COS characteristics, and severity classification. We also eliminated confounders by logistic regression when there were differences (P < 0.1) in baseline characteristics between the groups. Thus, the outcome results were likely to be related to the time window between the hysteroscopic adhesiolysis and the ET.

Discussion

In the present study, we determined the effect of the time window between hysteroscopic adhesiolysis and ET upon the outcomes of IVF/ICSI cycles. We found that the optimal waiting period for ET after hysteroscopic adhesiolysis was 90 to 180 days. Time intervals longer than 3 months should be used for improved ART outcomes.

Intra-uterine adhesions are a consequence of trauma to the endometrium and can lead to partial or complete endometrial dysfunction with impairment of fertility and the menstrual cycle (amenorrhea and hypomenorrhea).[1,14] For ART, IUAs require clinical management because they are associated with infertility and recurrent pregnancy loss.[8] Approximately 7% of patients present with a primary fertility complaint.[21] Moreover, recurrent implantation failure (RIF), the failure to conceive after three or more IVF or ET cycles, is also associated with IUAs.[22] Altered endometrial thickness and inflammation and can lead to IUAs that affect the outcome of IVF/ICSI.[7,23]

Patients should be encouraged to undergo second-look office hysteroscopy because of the high rate of recurrence of IUA after surgery and its significant effects on subsequent reproductive outcomes; office hysteroscopy can easily and effectively separate new adhesions.[24–26] In our study, all patients were treated with an artificial menstrual cycle for 1 to 2 months after hysteroscopic surgery, to allow recovery of the endometrium. Subsequently, patients underwent second-look hysteroscopy. Some patients had excellent outcomes and were able to start fresh IVF or ICSI cycles. But, if adhesion recurs, patients require reoperation and ART cycles will be delayed.

We examined ART outcomes to determine the optimal time to perform IVF after hysteroscopic adhesiolysis surgery. According to our results, Group 2 with a 90- to 180-day time interval had higher live-birth and ongoing pregnancy rates than the groups with less than 90-day (Group 1) or greater than 180-day (Group 3) time intervals. Furthermore, our first concerned outcome is live-birth rate. The live-birth rate was significantly higher in Group 2 than that in Group 1. The lack of a significant difference between Groups 2 and 3 may reflect the small sample size of Group 3 compared with the other two groups. From the ratio trend, we observed that the clinical miscarriage rate of Group 2 was lower than that of Groups 1 and 3, although the difference was not statistically significant. We propose that the optimal waiting period for ET after hysteroscopic adhesiolysis is 90 to 180 days. One explanation for the differences between Groups 1 and 2 may be that the wounds of adhesiolysis do not fully heal within 3 months. A thick endometrium is more favorable for embryo implantation and development,[7] and endometrium becomes thicker with a longer recovery time.[12,27] Our previous results of second-look surgery also showed that there was a better endometrial recovery and fewer abnormalities at 2 months compared with 1 month post-surgery. The clinical pregnancy rate of Group 3 was lower than that of Group 2, and the miscarriage rate was increased. It is possible explanation that the smaller sample size of Group 3 affected the outcomes. Alternatively, new IUAs may be formed after the second-look office hysteroscopy.

In the current study, patients exhibited IUAs with different degrees of severity. We further investigated whether there was a relationship between the degree of severity of IUAs and the optimal waiting periods for ET with respect to ART outcomes. In the mild and moderate IUA groups, significant differences were observed in the live-birth rate at the three different time intervals. In the mild subgroup, the live-birth rate was significantly higher in Group 2 than that in Group 1. In the moderate subgroup, the live-birth rate was also significantly higher in Group 2 than that in Group 1. This comparison indicates that the optimal waiting period of the moderate group is 90 to 180 days. We propose that the time interval for embryo transplantation after hysteroscopic adhesion separation should be no less than 3 months.

Our study demonstrated the effect of the time window between the hysteroscopic adhesiolysis and the ET upon IVF/ICSI cycle outcomes. The optimal time interval for embryo transplantation after hysteroscopic adhesion separation was 90 to 180 days. Shorter or longer time intervals reduced the pregnancy rate, which has significance for clinical ART. In addition, the severity and extent of IUAs were scored according to different classification systems. We further analyzed the outcomes of patients with different degrees of severity of IUA, to allow us to provide accurate advice to affected patients. However, our study has some limitations. First, this is a retrospective study that may include selection bias and diminish the strength of the current conclusions. There are many confounding factors that affect pregnancy outcomes; hence, we used the multifactor model as a statistical method of correction. Our total sample size was not large. Larger sample sizes are needed to confirm this outcome in a future study. The Group 3 sample size was less than the other two groups and may affect the outcomes. Future studies should examine a larger sample size, in particular for Group 3. Furthermore, new IUAs may form after the second-look office hysteroscopy; this may have affected the outcomes.

In conclusion, the time interval between hysteroscopic adhesion separation and the day of fresh ET affected the outcome of IVF/ICSI with fresh ET cycles. The optimal time interval for ET after hysteroscopic adhesion separation was 90 to 180 days, and the time interval should be no less than 3 months.

Acknowledgements

The authors are very grateful to the patients and all participants in the data collection.

Funding

This study was supported by the grants from the National Key Research and Development Program of China (No. 2018YFC1004801), the Key Research and Development Program of Shandong Province (No. 2015GSF118124), and Medical Science and Technology Development Plans in Shandong Province (No. 2016WS0369).

Conflicts of interest

None.

References

1. Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome--one century later. Fertil Steril 2008; 89:759–779. doi: 10.1016/j.fertnstert.2008.02.096.
2. Guo J, Li TC, Liu Y, Xia E, Xiao Y, Zhou F, et al. A prospective, randomized, controlled trial comparing two doses of oestrogen therapy after hysteroscopic adhesiolysis to prevent intrauterine adhesion recurrence. Reprod Biomed Online 2017; 35:555–561. doi: 10.1016/j.rbmo.2017.07.011.
3. Hooker AB, Lemmers M, Thurkow AL, Thukow AL, Hwymans MW, Opmeer BC, et al. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome. Hum Reprod Update 2014; 20:262–278. doi: 10.1093/humupd/dmt045.
4. Mo X, Qin G, Zhou Z, Jiang X. Assessment of risk factors of intrauterine adhesions in patients with induced abortion and the curative effect of hysteroscopic surgery. J Invest Surg 2019; 32:85–89. doi: 10.1080/08941939.2017.1376130.
5. Khan Z, Goldberg JM. Hysteroscopic management of Asherman's syndrome. J Minim Invasive Gynecol 2018; 25:218–228. doi: 10.1016/j.jmig.2017.09.020.
6. Barash A, Granot I, Fieldust S, Or Y. Successful pregnancy and delivery of a healthy baby after endometrial biopsy treatment in an in vitro fertilization patient with severe Asherman syndrome. Fertil Steril 2009; 91:1956.e1–1956.e3. doi: 10.1016/j.fertnstert.2009.01.128.
7. Lebovitz O, Orvieto R. Treating patients with “thin” endometrium - an ongoing challenge. Gynecol Endocrinol 2014; 30:409–414. doi: 10.3109/09513590.2014.906571.
8. Salazar CA, Isaacson K, Morris S. A comprehensive review of Asherman's syndrome: causes, symptoms and treatment options. Curr Opin Obstet Gynecol 2017; 29:249–256. doi: 10.1097/GCO.0000000000000378.
9. Bosteels J, Kasius J, Weyers S, Broekmans FJ, Mol BW, D Hooghe TM. Treating suspected uterine cavity abnormalities by hysteroscopy to improve reproductive outcome in women with unexplained infertility or prior to IUI, IVF, or ICSI. Gynecol Surg 2013; 10:165–167. doi: 10.1007/s10397-013-0798-0.
10. Di Spiezio Sardo A, Calagna G, Scognamiglio M, O’Donvan P, Campo R, De Wilde RL. Prevention of intrauterine post-surgical adhesions in hysteroscopy. A systematic review. Eur J Obstet Gynecol Reprod Biol 2016; 203:182–192. doi: 10.1016/j.ejogrb.2016.05.050.
11. Healy MW, Schexnayder B, Connell MT, Terry N, DeCherney AH, Csokmay JM, et al. Intrauterine adhesion prevention after hysteroscopy: a systematic review and meta-analysis. Am J Obstet Gynecol 2016; 215:267–275.e7. doi: 10.1016/j.ajog.2016.05.001.
12. Yang JH, Chen MJ, Chen CD, Chen SU, Ho HN, Yang YS. Optimal waiting period for subsequent fertility treatment after various hysteroscopic surgeries. Fertil Steril 2013; 99:2092–2096.e3. doi: 10.1016/j.fertnstert.2013.01.137.
13. Pereira N, Amrane S, Estes JL, Lekovich JP, Elias RT, Chung PH, et al. Does the time interval between hysteroscopic polypectomy and start of in vitro fertilization affect outcomes? Fertil Steril 2016; 105:539–544.e1. e5 doi: 10.1016/j.fertnstert.2015.10.028.
14. Conforti A, Alviggi C, Mollo A, De Placido G, Magos A. The management of Asherman syndrome: a review of literature. Reprod Biol Endocrinol 2013; 11:118doi: 10.1186/1477-7827-11-118.
15. The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, Müllerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49:944–955. doi: 10.1016/S0015-0282(16)59942-7.
16. AAGL Elevating Gynecologic Surgery. AAGL Practice Report: Practice Guidelines on intrauterine adhesions developed in collaboration with the European Society of Gynaecological Endoscopy (ESGE). J Minim Invasive Gynecol 2017; 24:695–705. doi: 10.1016/j.jmig.2016.11.008.
17. Chinese Medical Association Obstetrics and Gynecology Branch. Chinese expert consensus in clinical diagnosis and treatment of uterine adhesion [in Chinese]. Chin J Obstet Gynecol 2015; 50:881–887. doi: 10.3760/cma.j.issn.0529-567x.2015.12.001.
18. Guo T, Qin Y, Gao X, Chen H, Li G, Ma J, et al. The role of male chromosomal polymorphism played in spermatogenesis and the outcome of IVF/ICSI-ET treatment. Int J Androl 2012; 35:802–809. doi: 10.1111/j.1365-2605.2012.01284.x.
19. Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med 2016; 375:523–533. doi: 10.1056/NEJMoa1513873.
20. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, Sokol R, Rienzi L, et al. The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod 2017; 32:1786–1801. doi: 10.1093/humrep/dex234.
21. Hanstede MM, van der Meij E, Goedemans L, Emanuel MH. Results of centralized Asherman surgery, 2003–2013. Fertil Steril 2015; 104:1561–1568.e1. doi: 10.1016/j.fertnstert.2015.08.039.
22. Coughlan C, Yuan X, Nafee T, Yan J, Mariee N, Li TC. The clinical characteristics of women with recurrent implantation failure. J Obstet Gynaecol 2013; 33:494–498. doi: 10.3109/01443615.2013.782280.
23. Zhu HY, Ge TX, Pan YB, Zhang SY. Advanced role of Hippo signaling in endometrial fibrosis: implications for intrauterine adhesion. Chin Med J 2017; 130:2732–2737. doi: 10.4103/0366-6999.218013.
24. Robinson JK, Colimon LM, Isaacson KB. Postoperative adhesiolysis therapy for intrauterine adhesions (Asherman's syndrome). Fertil Steril 2008; 90:409–414. doi: 10.1016/j.fertnstert.2007.06.034.
25. Yu D, Li TC, Xia E, Huang X, Liu Y, Peng X. Factors affecting reproductive outcome of hysteroscopic adhesiolysis for Asherman's syndrome. Fertil Steril 2008; 89:715–722. doi: 10.1016/j.fertnstert.2007.03.070.
26. Xu W, Zhang Y, Yang Y, Zhang S, Lin X. Effect of early second-look hysteroscopy on reproductive outcomes after hysteroscopic adhesiolysis in patients with intrauterine adhesion, a retrospective study in China. Int J Surg 2018; 50:49–54. doi: 10.1016/j.ijsu.2017.11.040.
27. Baradwan S, Shafi D, Baradwan A, Bashir MS, Al Jaroudi D. The effect of endometrial thickness on pregnancy outcome in patients with Asherman's syndrome post-hysteroscopic adhesiolysis. Int J Womens Health 2018; 10:77–82. doi: 10.2147/IJWH.S151283.
Keywords:

Asherman syndrome; Hysteroscopy; In vitro fertilization

Supplemental Digital Content

© 2019 by Lippincott Williams & Wilkins, Inc.